Better Therapeutics Inc.’s prescription digital therapeutic (PDT) received U.S. FDA breakthrough device designation for metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease that increases the risk of cirrhosis, liver failure and liver cancer but has few good treatments available.
The analysis of several oral antidiabetic drugs revealed patients taking SGLT2 inhibitors had more NAFLD regression and fewer adverse liver-related outcomes.
HealthFLD, a fully automated AI software for liver attenuation analysis from CT scans, has received FDA 510(k) clearance for use in the general population.
Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.
Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.